The American Diabetes Association (ADA) Standards of Care emphasize that diabetes is a progressive condition requiring ongoing pharmacological management in most patients, and discontinuing effective therapy typically results in deterioration of glycemic control
Iyer, R., Gupta, A., Khan, A., Hiremath, S., and Lokhandwala, Y
Because aspiration is a rare event, it may be a long time before we can know with high-quality evidence whether GLP-1 RA use increases aspiration risk
The KLOW peptide is thought to support mitochondrial biogenesis and function, leading to more efficient energy production
(28152637) IV L-arginine might be a reasonable consideration in the following situations: i) Moderate to severe hyperammonemia, without immediate access to hemodialysis ii) Persistent hyperammonemia, despite hemodialysis iii) Hyperammonemia which poses an immediate threat to life (e.g., moderate to severe hyperammonemia with evidence of cerebral edema) A reasonable dose may be: (22642880) Loading bolus of 250 mg/kg (1.2 mM/kg) over 2 hours
Comment: While many commenters indicated that our proposed changes to the HPT requirements outlined in the CY 2026 OPPS/ASC proposed rule and/or the HPT requirements in general are burdensome, as discussed in prior sections of this final rule with comment period, only several commenters commented on our specific burden estimates for these information collections
